| Document |
Document Title |
|
WO/2023/154282A1 |
Provided herein are compounds and compositions thereof that may be capable of disrupting, interrupting, and/or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provide...
|
|
WO/2023/153169A1 |
The present disclosure provides an organic compound represented by general formula (1). (In general formula (1), R1 to R20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, an...
|
|
WO/2023/150236A1 |
Processes and methods of preparing Compound (I) are disclosed. Crystalline forms of Compound (I), pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of ...
|
|
WO/2023/148129A1 |
The present invention relates to compounds of formula (Ia), (Ia), wherein R2, M1, M2, M3, Q1 and Q2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of usin...
|
|
WO/2023/148501A1 |
The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2023/147678A1 |
The present invention relates to a method for synthesising the compound desmethylxestospongin B (dmXeB), wherein an esterification of azidoalcohol 4 with 2-(benzyloxy)-5-chloropentanoic acid 5 or 5-chloropentanoic acid is performed to ob...
|
|
WO/2023/149038A1 |
A compound or a pharmaceutically acceptable salt thereof of the present invention has a structure represented by formula (I) and can form a ligand in a drug delivery system formulation. The drug delivery system formulation according to t...
|
|
WO/2023/150374A1 |
The present disclosure provides compounds that are inducers of KLF2 and pharmaceutical compositions comprising the same. The present disclosure further provides method of treating an inflammatory disease or endothelial dysfunction compri...
|
|
WO/2023/143079A1 |
The present invention relates to a crystal form of the compound (2 2R,2 4S,5S)-2 4,3 5-difluoro-5-methyl-4-oxa-7,9-diaza-1(5,3)-pyrazolo[1,5-a]py
rimidin-3(3,2)-pyridin-2(1,2)-pyrrolidine cyclononane-8-one of formula (I) and a preparatio...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143589A1 |
The present invention relates to a compound represented by formula (I), or an isomer, isotope derivative, polymorph, prodrug thereof, or a pharmaceutically acceptable salt or solvate thereof: wherein R1, R2, R3a, R3b, R3c, R3d, W1, W2, G...
|
|
WO/2023/144297A1 |
The present disclosure relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments ...
|
|
WO/2023/144793A1 |
The present invention relates to compounds of formula (I), that possess DNA polymerase theta (POLQ) enzyme inhibitory activity, methods for their preparation, pharmaceutical compositions containing them, and their use in the treatment or...
|
|
WO/2023/143389A1 |
The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
|
|
WO/2023/144559A1 |
The present invention relates to compounds of formula I shown below: wherein R1, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...
|
|
WO/2023/143623A1 |
Disclosed are a quinoline compound and the use thereof. The quinoline compound is a compound as represented by formula (I), formula (II) or formula (III), a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer ther...
|
|
WO/2023/144379A1 |
The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In par...
|
|
WO/2023/147418A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, togeth...
|
|
WO/2023/139085A1 |
The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2023/141300A1 |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
|
|
WO/2023/138343A1 |
The present invention relates to a new type pyrazolopyrimidine compound, a composition thereof, a preparation method therefor and the use thereof as an anti-cancer drug having anti-tumor activity. The new type pyrazolopyrimidine compound...
|
|
WO/2023/139199A1 |
Compounds of Formula (I) or a pharmaceutically acceptable salt thereof are PROTAC compounds useful in the treatment of prostate cancer.
|
|
WO/2023/141511A1 |
5,6,7,8-Tetrahydro-1,6-naphthyridines substituted in the 6-position with pyrimido[1,2-b]pyridazin-4-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological a...
|
|
WO/2023/138317A1 |
Disclosed are a compound having RIPK1 inhibitory activity, a preparation method therefor and the use thereof. The structure of the compound is as shown in general formula I, and the definition of each substituent is as described in the d...
|
|
WO/2023/137035A1 |
Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of ...
|
|
WO/2023/134752A1 |
The present invention provides a diaryl compound as a tubulin/Src dual target inhibitor. The present invention also provides a diaryl compound represented by formula I, a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable...
|
|
WO/2023/135528A1 |
The present invention relates to heteroalicyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes a method of mak...
|
|
WO/2023/134708A1 |
Provided are compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including ...
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/131868A1 |
The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of GLUT9 for the treatment or prevention of hyperuricemia and gout.
|
|
WO/2023/131122A1 |
Disclosed in the present invention is a compound as represented by formula (IA) or formula (IC) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The definition of each group in the formula is shown i...
|
|
WO/2023/125486A1 |
Provided are a class of compounds which have a structure as shown in the following general formula (I) and are used as somatostatin receptor subtype 5 (SSTR5) antagonists, and a pharmaceutical composition and the use thereof. The compoun...
|
|
WO/2023/125918A1 |
The present invention discloses a DNA polymerase theta inhibitor and the use thereof. Specifically, the present invention provides a compound as shown in formula (I) or formula (II), or a tautomer thereof, a stereoisomer thereof, a pharm...
|
|
WO/2023/127012A1 |
Provided is a therapeutic drug that is useful for treating aneurysm. A medicinal composition for treating and/or preventing aneurysm that comprises at least one of the following agents i) to iii) as an active ingredient. i) An agent ...
|
|
WO/2023/123655A1 |
The present invention relates to a preparation method for a 3-substituted-9-methyl-thieno-triazolooxazine compound, and overcomes the defects of long route (14 steps), low yield and low atom economy in the prior art. In the present inven...
|
|
WO/2023/121321A1 |
The present invention relates to a use of Asaroidoxazine B having anticancer activity and, more specifically, to: a pharmaceutical composition and a health functional food composition, each utilizing Asaroidoxazine B represented by chemi...
|
|
WO/2023/121311A1 |
The present invention relates to novel asaroidoxazine C and an anti-cancer use thereof. More specifically, provided are: asaroidoxazine C represented by Formula 1 below, an isomer thereof, or a pharmaceutically acceptable salt thereof; a...
|
|
WO/2023/118875A1 |
The invention relates to a compound of formula (I) which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3
-yl)methyl)phthalazin-1(2H)- one; or a salt and/or solvate thereof; and to its use in treating or preventing an infl...
|
|
WO/2023/121320A1 |
The present invention relates to an anticancer use of aristoloxazine C and, more specifically, to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by chemical formula 1 or an is...
|
|
WO/2023/116866A1 |
A five- and six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory...
|
|
WO/2023/118319A1 |
The present disclosure relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments,...
|
|
WO/2023/121413A1 |
The present invention relates to: a novel bicyclic heterocyclyl compound which has an SOS1 inhibitory activity and thus may be utilized for preventing, relieving or treating various carcinomas or RASopathy; a stereoisomer thereof; a solv...
|
|
WO/2023/115203A1 |
Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
|
|
WO/2023/114710A1 |
The present invention provides fused benzoisoxazolyl compounds represented by compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of the diseases or disorders medi...
|
|
WO/2023/112056A1 |
The present invention provides a compound formula (I), Formula (I) wherein, R1, R2, R3, R5, R6, R7, R8, R9, X, Z1 and Z2 are as defined in the detailed description and a process for preparing the compound of formula (I). The present inve...
|
|
WO/2023/114823A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung d...
|
|
WO/2023/109909A1 |
Aromatic heterocyclic compounds as ENPP1 inhibitors, a preparation method therefor and the uses thereof. The compounds have structures as shown in formula (I).
|
|
WO/2023/114365A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2023/114822A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/111125A1 |
Method of making Buprenorphine comprising a Grignard reaction, comprising step (A): (A) performing the Grignard reaction in the presence of a compound of formula IIIa or IIIf R1-[O-CHR2-CHR3]n-OR4 IIIa wherein n is an integer in the rang...
|
